Cough syrup deaths: WHO asks countries to act on fake drugs : The Tribune India

Spurious Drugs

Cough syrup deaths: WHO asks countries to act on fake drugs

Cough syrup deaths: WHO asks countries to act on fake drugs

Photo for representational purpose only. - File photo



Geneva, January 24

In the wake of fatalities among children linked to cough syrups and medicines made by manufacturers based in India and Indonesia, the WHO has issued an “urgent call to action” to countries to detect and respond to incidents of falsified medical products and protect children from contaminated medicines.

The World Health Organisation (WHO) said that over the past four months, countries reported several incidents of over-the-counter cough syrups for children with confirmed or suspected contamination with high levels of diethylene glycol (DEG) and ethylene glycol (EG).

The cases are from at least seven countries, associated with more than 300 fatalities in three of these countries, with most young children under the age of five. The WHO said the contaminants are toxic chemicals used as industrial solvents and antifreeze agents that can be fatal even in small amounts, and should never be found in medicines.

“WHO is releasing an urgent call to action to countries to prevent, detect and respond to incidents of substandard and falsified medical products,” the global health agency said.

Since October last year, the WHO has issued three medical alerts over substandard paediatric medicines and syrups. In October 2022, it issued an alert over Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup manufactured by Maiden Pharmaceuticals Limited, Haryana, India.

The four “substandard products” were identified in the Gambia and reported to the WHO in September 2022.

In November, an alert was issued by the WHO over eight products, including Unibebi Cough Syrup, Unibebi Demam Paracetamol Drops and Unibebi Demam Paracetamol Syrup, identified in Indonesia and manufactured by PT Afi Farma.

Earlier this month, the WHO issued an alert to warn against the use of two “substandard” cough syrups manufactured by Marion Biotech, India that have been linked to the deaths of 18 children in Uzbekistan. Ambronol syrup and DOK-1 Max syrup were manufactured by Marion Biotech, based in Noida, Uttar Pradesh.

The global health organisation issued the alert saying the syrups fail to meet quality standards and contain contaminants that can prove fatal.

The WHO’s medical product alerts were rapidly disseminated to the national health authorities of all 194 WHO Member States. — PTI

Over 300 dead in three countries

  • Suspected contamination with high levels of diethylene glycol and ethylene glycol in cough syrups
  • Cases from at least seven countries, associated with more than 300 fatalities in three of these countries
  • The contaminants are toxic chemicals used as industrial solvents and antifreeze agents
  • Deaths linked to cough syrups, medicines made by manufacturers based in India and Indonesia

Tribune Shorts


Top News

8 charred to death in massive fire at multi-storey building in Jharkhand’s Dhanbad

14 charred to death in massive fire at building in Jharkhand’s Dhanbad

Around 40 fire tenders were pressed into service to douse th...

Budget 2023-24: Tax sops, fiscal consolidation tightrope walk for Sitharaman

Budget 2023-24: Tax sops, fiscal consolidation tightrope walk for Finance Minister Sitharaman

Despite this being last Budget before general elections, big...

India's economy to grow  6.5 per cent in 2023-24: Economic survey

India's economy to grow 6.5 per cent in 2023-24: Economic survey

The survey said the pace of price increases is not high enou...

Asaram gets life imprisonment in 2013 rape case

Gujarat: Court sentences Asaram to life imprisonment in 2013 rape case

81-year-old is currently lodged in a Jodhpur jail, where he ...

Decriminalisation of adultery won’t be applicable in armed forces, rules SC

Decriminalisation of adultery won’t be applicable in armed forces, rules SC

Top court clarifies its 2018 landmark verdict which had stru...


Cities

View All